Pigment epithelial changes with abnormal fundus autofluorescence after photodynamic therapy for idiopathic choroidal neovascularization.
Wakabayashi
Taku
T
Department of Ophthalmology, Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Gomi
Fumi
F
Department of Ophthalmology, Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan. fgomi@ophthal.med.osaka-u.ac.jp.
Sawa
Miki
M
Department of Ophthalmology, Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Shiraki
Kunihiko
K
Department of Ophthalmology and Visual Sciences, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Tano
Yasuo
Y
Department of Ophthalmology, Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D005453:Fluorescence; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D009887:Ophthalmoscopy; D010778:Photochemotherapy; D010857:Pigment Epithelium of Eye / Q000187:drug effects* / Q000473:pathology; D011183:Postoperative Complications; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab